Literature DB >> 9314868

New variant Creutzfeldt-Jakob disease: psychiatric features.

M Zeidler1, E C Johnstone, R W Bamber, C M Dickens, C J Fisher, A F Francis, R Goldbeck, R Higgo, E C Johnson-Sabine, G J Lodge, P McGarry, S Mitchell, L Tarlo, M Turner, P Ryley, R G Will.   

Abstract

BACKGROUND: An apparently new variant of Creutzfeldt-Jakob disease (CJD), new variant CJD (nvCJD), was identified in the UK in 1996. There have now been 21 cases of nvCJD in the UK and one in France. Psychiatric symptoms are prominent in the initial presentation in these cases.
METHODS: Cases of nvCJD are identified mainly by direct referral from neurologists and neuropathologists. Detailed clinical information was obtained by review of case notes and interviewing patients' relatives. We report the psychiatric features of the first 14 cases on nvCJD in the UK. Psychiatric notes were examined in all 13 of these cases who were seen by a psychiatrist.
RESULTS: Eight cases were women. All 14 cases had early psychiatric features and in nine, the first symptom was psychiatric. 13 cases were seen by a psychiatrist and the majority were diagnosed as suffering from depression or depression secondary to organic disease. Two cases suffered from first-rank symptoms suggestive of psychotic illness and transient delusions and auditory or visual hallucinations occurred in the majority. All cases were referred to a neurologist as the illness evolved and neurological signs developed.
INTERPRETATION: Psychiatric symptoms are a consistent early clinical feature in nvCJD. Analysis of the psychiatric symptoms does not suggest specific features that readily allow distinction from more common psychiatric disorders, although the occurrence of associated persistent sensory symptoms may raise the possibility of this diagnosis. Neurological signs, including ataxia, involuntary movements and cognitive impairment developed in all cases and the evolution of increasing neurological deficits is likely to remain critical to the clinical diagnosis of nvCJD.

Entities:  

Mesh:

Year:  1997        PMID: 9314868     DOI: 10.1016/s0140-6736(97)03148-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  23 in total

1.  Progressive aphasia with rapidly progressive dementia in a 49 year old woman.

Authors:  J D Greene; J R Hodges; J W Ironside; C P Warlow
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-02       Impact factor: 10.154

2.  New-variant Creutzfeldt-Jacob disease.

Authors:  G Smith; R Charlton
Journal:  Br J Gen Pract       Date:  2000-08       Impact factor: 5.386

Review 3.  Neurological and cognitive decline in adolescence.

Authors:  Rob J Forsyth
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-03       Impact factor: 10.154

4.  Creutzfeldt-Jakob disease and infection control.

Authors:  L Johnston; J Conly
Journal:  Can J Infect Dis       Date:  2001-11

5.  Rapidly progressive young-onset dementia.

Authors:  Brendan J Kelley; Bradley F Boeve; Keith A Josephs
Journal:  Cogn Behav Neurol       Date:  2009-03       Impact factor: 1.600

Review 6.  Variant Creutzfeldt-Jakob disease: a summary of current scientific knowledge in relation to public health.

Authors:  M B Coulthart; N R Cashman
Journal:  CMAJ       Date:  2001-07-10       Impact factor: 8.262

7.  Distinct neuropsychological characteristics in Creutzfeldt-Jakob disease.

Authors:  J S Snowden; D M A Mann; D Neary
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-12       Impact factor: 10.154

8.  Ethics in prion disease.

Authors:  Kendra Bechtel; Michael D Geschwind
Journal:  Prog Neurobiol       Date:  2013-07-29       Impact factor: 11.685

Review 9.  First hundred cases of variant Creutzfeldt-Jakob disease: retrospective case note review of early psychiatric and neurological features.

Authors:  Michael D Spencer; Richard S G Knight; Robert G Will
Journal:  BMJ       Date:  2002-06-22

10.  Creutzfeldt-Jakob disease in Sweden.

Authors:  P O Lundberg
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-12       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.